助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   autologous transplant 在 儿科学 分类中 的翻译结果: 查询用时:0.05秒
图标索引 在分类学科中查询
所有学科
儿科学
肿瘤学
更多类别查询

图标索引 历史查询
 

autologous transplant
相关语句
  “autologous transplant”译为未确定词的双语例句
    Methods Retrospective analysis for autologous transplant mainly with intravenous melphalan in 43 children with advanced malignant solid tumours was performed in our center.
    方法用回顾性分析的方法,对43例以静脉马法兰为主的预处理移植治疗的儿童高危恶性肿瘤临床资料进行分析。
短句来源
    Totally 45 autologous transplant were finished among these 43 patients because 2 patients received 2 consecutive transplants including 8 with bone marrow transplant and 37 with peripheral precursor transplant. The dosage of melphaelan was 140 mg/m2 in 8 cases, 180 mg/m2 in 10 cases and 210 mg/m2 in rest of 27 cases.
    因2例患儿连续进行2次移植,43例患儿共进行45例次移植,8例为骨髓移植、37例次为外周血造血干细胞移植,8例次患儿应用140mg/m2马法兰,10例应用180mg/m2马法兰,其余27例次应用210mg/m2马法兰。
短句来源
    Report on the autologous transplant mainly conditioned with intravenous melphalan in 43 chinese children with advanced malignant solid tumours
    以静脉马法兰为主的预处理自身移植治疗43例儿童高危恶性实体肿瘤
短句来源
查询“autologous transplant”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  autologous transplant
Although autologous transplantation has improved outcomes for younger patients, the use of a second autologous transplant in the relapsed setting has less benefit.
      
Therapeutic options for patients with hodgkin's disease and non-hodgkin's lymphoma who relapse after autologous transplant
      
Allogeneic transplant patients reported higher pain intensity than did autologous transplant patients.
      
One case was positive at the beginning of CR and became negative after autologous transplant.
      
Peripheral blood stem cell CD34+ autologous transplant in relapsed follicular lymphoma
      
更多          


Objective To evaluate the safety and efficiency of conditioning regimen mainly with intravenous melphalan for children with advanced malignant solid tumours and explore the appropriate dosage of memlphalan for Chinese children. Methods Retrospective analysis for autologous transplant mainly with intravenous melphalan in 43 children with advanced malignant solid tumours was performed in our center. Carboplatin 350 mg/m2·d×2 d+VP16 300 mg/m2·d×2d and intravenous melphalan 140 mg/m2 were used for bone marrow...

Objective To evaluate the safety and efficiency of conditioning regimen mainly with intravenous melphalan for children with advanced malignant solid tumours and explore the appropriate dosage of memlphalan for Chinese children. Methods Retrospective analysis for autologous transplant mainly with intravenous melphalan in 43 children with advanced malignant solid tumours was performed in our center. Carboplatin 350 mg/m2·d×2 d+VP16 300 mg/m2·d×2d and intravenous melphalan 140 mg/m2 were used for bone marrow transplant. Carboblatin 300 mg/m2·d×4d, VP16 160 mg/m2·d×4d and intravenous melphalan 210 mg/m2 were used for peripheral stem cell transplant. 180 mg/m2 melphalan was used for the patients when the hematological function couldn't recover within 30 days after chemotherapy or the number of nuclear cell in autograft was less than 3×108/kg. The side-effects were monitored and the speed of hematopoietic rehabilitation and the prognosis for these patients were evaluated. Results Mean age of this group was 7.6±4.2(1~17) years and mean body weight was 26.8±13.9 (9.5~52) kg. Totally 45 autologous transplant were finished among these 43 patients because 2 patients received 2 consecutive transplants including 8 with bone marrow transplant and 37 with peripheral precursor transplant. The dosage of melphaelan was 140 mg/m2 in 8 cases, 180 mg/m2 in 10 cases and 210 mg/m2 in rest of 27 cases. Diarrhea was the most common side effect which occurred in 26 cases (57%) after 2~3 days of melphalan administration accompanied abdominal pain, discomfort in precardiac region and oral mucositis lasting 3~7 days. All the patients with the mean time for absolute neutrophil over 0.5×109/L was 11.4±8.5 days and palate over 20×109/L was 21.4±9.5 except one who received melphalan 180 mg/m2 had poor recovery of the hematopoietic function after transplantation. There was no significant difference of hematologic recovery between patients received different dosage of melphalan. The mean duration for following up lasted for 16.1±14.2 months (2~65 months), 17 cases (39%) relapsed with mean period 14.2±9.68 (3~34) months post transplant, among them 12 was neuroblastoma. 26 children (61%) are still remaining disease free survival. No transplant related mortality could be found in our group up to now. Conclusion The conditioning regimen consisting of melphalan 180 mg/m2~210 mg/m2 and combination of carboplatin VP16 was safe and effective for the Chinese children with advanced malignant solid tumours. The common side effect in intravenous melphalan is mucositis. 210 mg/m2 of melphalan should be considered as the right dosage when the number of stem cells is enough and the potential of bone marrow recovery is good after sequence chemotherapy. The regimen for patients with advanced neuroblastoma should be further explored.

目的评价以静脉马法兰为主的预处理方案自身移植治疗儿童高危恶性实体肿瘤的安全性、有效性,探索中国儿童合适的静脉马法兰剂量。方法用回顾性分析的方法,对43例以静脉马法兰为主的预处理移植治疗的儿童高危恶性肿瘤临床资料进行分析。骨髓移植者采用卡铂350mg/m2.d×2+足叶乙甙(VP16)300mg/m2.d×2+马法兰(总量140mg/m2),外周血干细胞移植者采用卡铂300mg/m2.d×4+VP16160mg/m2.d×4+马法兰总量210mg/m2(移植前化疗休疗≥30天血象尚不能恢复正常或自身干细胞采集有核细胞数量不足3×108/kg者选用180mg/m2马法兰),临床观察药物的毒副反应并评估造血重建速度及患者预后。结果本组平均年龄7.6±4.2(1~17)岁,平均体重26.8±13.9(9.5~52)kg。因2例患儿连续进行2次移植,43例患儿共进行45例次移植,8例为骨髓移植、37例次为外周血造血干细胞移植,8例次患儿应用140mg/m2马法兰,10例应用180mg/m2马法兰,其余27例次应用210mg/m2马法兰。马法兰使用后26例次(57%)患儿出现腹泻,大多伴有腹痛、心前区不适及口腔黏膜炎,除...

目的评价以静脉马法兰为主的预处理方案自身移植治疗儿童高危恶性实体肿瘤的安全性、有效性,探索中国儿童合适的静脉马法兰剂量。方法用回顾性分析的方法,对43例以静脉马法兰为主的预处理移植治疗的儿童高危恶性肿瘤临床资料进行分析。骨髓移植者采用卡铂350mg/m2.d×2+足叶乙甙(VP16)300mg/m2.d×2+马法兰(总量140mg/m2),外周血干细胞移植者采用卡铂300mg/m2.d×4+VP16160mg/m2.d×4+马法兰总量210mg/m2(移植前化疗休疗≥30天血象尚不能恢复正常或自身干细胞采集有核细胞数量不足3×108/kg者选用180mg/m2马法兰),临床观察药物的毒副反应并评估造血重建速度及患者预后。结果本组平均年龄7.6±4.2(1~17)岁,平均体重26.8±13.9(9.5~52)kg。因2例患儿连续进行2次移植,43例患儿共进行45例次移植,8例为骨髓移植、37例次为外周血造血干细胞移植,8例次患儿应用140mg/m2马法兰,10例应用180mg/m2马法兰,其余27例次应用210mg/m2马法兰。马法兰使用后26例次(57%)患儿出现腹泻,大多伴有腹痛、心前区不适及口腔黏膜炎,除1例应用马法兰180mg/m2患儿出现移植后造血功能恢复不良外,其余患儿平均11.4±8.5天中性粒细胞>0.5×109/L,21.4±9.5天血小板恢复至20×109/L以上。3个不同马法兰剂量组间造血恢复能力无明显差异。本组平均随访16.1±14.2个月(2~65个月),17例(39%)患儿平均移植后14.2±9.6个月(3~34个月)复发,其中12例为神经母细胞瘤。本组无移植相关的死亡,迄今仍有26例(61%)患儿处于无病生存状态。结论180mg/m2~210mg/m2的马法兰结合卡铂(300mg/m2.d×4)+VP16(160mg/m2.d×4天)用于自身造血干细胞移植治疗儿童晚期恶性实体肿瘤是安全有效的;黏膜炎是静脉马法兰应用后最常见的副反应;对于干细胞数量充足、化疗后骨髓恢复能力尚佳的移植患者以210mg/m2的马法兰剂量为妥;晚期神经母细胞瘤的治疗有待于探索更有效的方案。

 
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关autologous transplant的内容
在知识搜索中查有关autologous transplant的内容
在数字搜索中查有关autologous transplant的内容
在概念知识元中查有关autologous transplant的内容
在学术趋势中查有关autologous transplant的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社